23 Many Government Policies and Practices Encourage Off-Label Prescribing National Cancer Institute website, www.cancer.gov The National Cancer Instit
{"Image DocumentName": "Many Government Policies and Practices Encourage Off-Label Prescribing", "Image ImageDescription": "The National Cancer Institute recognized off-label indications of Rituxan as standard of care. Front Line Aggressive Adult Non-Hodgkin\u2019s Lymphoma: Standard treatment options: \u2026 1. CHOP plus rituximab Indolent, Noncontiguous Stage II/III/IV Adult Non-Hodgkin\u2019s Lymphoma: Standard treatment options: \u2026 1. Rituximab may be considered as first line therapy Stage I, II, III, and IV Chronic Lymphocytic Leukemia: Treatment options: \u2026 2. Rituximab, and anti-CD20 monoclonal antibody. National Cancer Institute website,", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}